As a proof of concept, CAR-T cells transduced with CD32A or CD16 in combination with cetuximab, achieved a greater cytotoxic response and improved survival of a CRC mouse model bearing EGFR mutations compared to either treatment alone (141, 142). The gene discussed is EGFR; the disease is colorectal carcinoma.